Zhou Delian, Zhu Xiaojian, Xiao Yi
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Biomark Res. 2024 Nov 6;12(1):132. doi: 10.1186/s40364-024-00679-6.
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue to be encountered, unlike its success in hematological malignancies such as acute lymphoblastic leukemia and diffuse large B-cell lymphomas. This review examined the research progress of chimeric antigen receptor T-cell therapy in gliomas, medulloblastomas, and lymphohematopoietic tumors of the central nervous system, focusing on chimeric antigen receptor T-cells targeting antigens such as EGFRvIII, HER2, B7H3, GD2, and CD19 in preclinical and clinical studies. It synthesized current research findings to offer valuable insights for future chimeric antigen receptor T-cell therapeutic strategies for central nervous system tumors and advance the development and application of this therapeutic modality in this domain.
嵌合抗原受体T细胞疗法在中枢神经系统肿瘤中的应用取得了显著进展；然而，与它在急性淋巴细胞白血病和弥漫性大B细胞淋巴瘤等血液系统恶性肿瘤中的成功不同，在血脑屏障、免疫抑制微环境和抗原异质性方面仍然面临挑战。本综述研究了嵌合抗原受体T细胞疗法在神经胶质瘤、髓母细胞瘤和中枢神经系统淋巴造血肿瘤中的研究进展，重点关注临床前和临床研究中针对表皮生长因子受体III型变异体（EGFRvIII）、人表皮生长因子受体2（HER2）、B7同源蛋白3（B7H3）、二唾液酸神经节苷脂（GD2）和CD19等抗原的嵌合抗原受体T细胞。它综合了当前的研究结果，为未来中枢神经系统肿瘤的嵌合抗原受体T细胞治疗策略提供有价值的见解，并推动这种治疗方式在该领域的开发和应用。
